The DOI matches its Crossref record.
Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens
Abstract
Apoptosis, programmed cell death, was previously shown to be induced by the mAb anti-APO-1 (IgG3, kappa) by binding to the APO-1 cell surface Ag, a new member of the nerve growth factor/TNF receptor superfamily. To investigate the role of the Ig H chain Fc regions we compared induction of apoptosis by the original mAb IgG3 anti-APO-1 with anti-APO-1 F(ab’)2 fragments and different anti-APO-1 isotypes (IgG1, IgG2b, IgG2a, and IgA) isolated by sequential sublining. We found that IgG3 was the most active isotype; IgG1, IgG2a, and IgA showed intermediate activity, and IgG2b and F(ab’)2 were inactive. Cytotoxic activity of the inactive or less active antibody preparations was fully reconstituted by protein A, anti-mouse Ig, or anti-mouse Ig F(ab’)2, respectively. Thus, APO-1-mediated induction of apoptosis was dependent on efficient cross-linking of APO-1 cell surface Ag, indirectly augmented by anti-APO-1 Fc-Fc self-aggregation. Because of their different in vitro activity we selected IgG3-, IgG2b-, and IgA anti-APO-1 to test their antitumor activity against solid human B lymphoblastoid tumors in SCID mice. The isotypes showed a different serum half-life (IgG3: 9.2-10.4 days, IgG2b: 1.9-2.6 days, and IgA: 14.1-29.2 h) and a different initial tumor localization 4 h after i.p. injection (IgG3 around the blood vessels, IgG2b homogeneously, and IgA heterogeneously distributed in the tumor). All antibody preparations induced tumor regression by induction of apoptosis, even IgG2b anti-APO-1 inactive in vitro without cross-linking. The activity of IgA anti-APO-1, which did not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity indicates that apoptosis may be used as the main if not the only mechanism of induction of tumor regression in vivo. As with in vitro, IgG3 anti-APO-1 was the most effective isotype also in vivo. This result suggests that cross-linking of APO-1 on the tumor cell surface may also be required for tumor regression by apoptosis in vivo. Taken together, our data show that selective targeting of apoptosis to tumors may be an efficient antitumor mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Suda, T., Takahashi, T., Golstein, P., & Nagata, S. (1993) · Cell · doi:10.1016/0092-8674(93)90326-l · Cited by 2,489
Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., & Peter, M. E. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00245.x · Cited by 2,184
Self-citationApoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & Harmon, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j · Cited by 2,132
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., & Krammer, P. H. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,609
Self-citationTUMOR NECROSIS FACTOR RECEPTOR AND Fas SIGNALING MECHANISMS
Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V., & Boldin, M. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.331 · Cited by 1,312
Apoptosis and Clearance of Apoptotic Cells
Nagata, S. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053010 · Cited by 1,103
Stanger, B. Z., Leder, P., Lee, T.-H., Kim, E., & Seed, B. (1995) · Cell · doi:10.1016/0092-8674(95)90072-1 · Cited by 971
Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1361 · Cited by 897
Self-citationp53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Self-citationNagata, S. (1999) · Annual Review of Genetics · doi:10.1146/annurev.genet.33.1.29 · Cited by 779
Chinnaiyan, A. M., Tepper, C. G., Seldin, M. F., O'Rourke, K., Kischkel, F. C., Hellbardt, S., Krammer, P. H., Peter, M. E., & Dixit, V. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.4961 · Cited by 767
Self-citationMüller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119174 · Cited by 748
Self-citationInvolvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
Galle, P. R., Hofmann, W. J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H., & Runkel, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1223 · Cited by 692
Self-citationExpression of the functional soluble form of human fas ligand in activated lymphocytes.
Tanaka, M., Suda, T., Takahashi, T., & Nagata, S. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07096.x · Cited by 638
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 628
Self-citationKägi, D., Ledermann, B., Bürki, K., Zinkernagel, R. M., & Hengartner, H. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.207 · Cited by 588
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase.
Cifone, M. G., De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., & Testi, R. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1547 · Cited by 573
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Drappa, J., Vaishnaw, A. K., Sullivan, K. E., Chu, J.-L., & Elkon, K. B. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352204 · Cited by 480
Recruitment of TNF Receptor 1 to Lipid Rafts Is Essential for TNFα-Mediated NF-κB Activation
Legler, D. F., Micheau, O., Doucey, M.-A., Tschopp, J., & Bron, C. (2003) · Immunity · doi:10.1016/s1074-7613(03)00092-x · Cited by 466
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
CD95(APO-1/Fas)-Mediated Apoptosis: Live and Let Die
Krammer, P. H. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60402-2 · Cited by 394
Self-citationBoldin, M. P., Mett, I. L., Varfolomeev, E. E., Chumakov, I., Shemer-Avni, Y., Camonis, J. H., & Wallach, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.1.387 · Cited by 387
Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death.
Jacobsen, M. D., Weil, M., & Raff, M. C. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.5.1041 · Cited by 367
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
M. Chinnaiyan, A., & Dixit, V. M. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00541-9 · Cited by 347
Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., & Fontana, A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117462 · Cited by 345
Self-citationFas and Fas Ligand: A Death Factor and Its Receptor
Nagata, S. (1994) · Advances in Immunology · doi:10.1016/s0065-2776(08)60672-0 · Cited by 338
Regulation of apoptosis in the immune system
Krammer, P. H., Behrmann, I., Daniel, P., Dhein, J., & Debatin, K.-M. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90102-3 · Cited by 308
Self-citationMöller, P., Koretz, K., Leithäuser, F., Brüderlein, S., Henne, C., Quentmeier, A., & Krammer, P. H. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570314 · Cited by 306
Self-citationOnto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304
Schulze-Osthoff, K., Krammer, P. H., & Dröge, W. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06780.x · Cited by 303
Self-citationCell Death by Apoptosis in Epidermal Biology
Haake, A. R., & Polakowska, R. R. (1993) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12363594 · Cited by 288
Strand, S., Hofmann, W. J., Grambihler, A., Hug, H., Volkmann, M., Otto, G., Wesch, H., Mariani, S. M., Hack, V., Stremmel, W., et al. (1998) · Nature Medicine · doi:10.1038/nm0598-588 · Cited by 278
Self-citationSchattner, E. J., Elkon, K. B., Yoo, D. H., Tumang, J., Krammer, P. H., Crow, M. K., & Friedman, S. M. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1557 · Cited by 278
Self-citationThe Fas–FADD death domain complex structure reveals the basis of DISC assembly and disease mutations
Wang, L., Yang, J. K., Kabaleeswaran, V., Rice, A. J., Cruz, A. C., Park, A. Y., Yin, Q., Damko, E., Jang, S. B., Raunser, S., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1920 · Cited by 276
TAp63α induces apoptosis by activating signaling via death receptors and mitochondria
Gressner, O., Schilling, T., Lorenz, K., Schulze Schleithoff, E., Koch, A., Schulze‐Bergkamen, H., Maria Lena, A., Candi, E., Terrinoni, A., Valeria Catani, M., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600708 · Cited by 255
Self-citationRudi, J., Kuck, D., Strand, S., von Herbay, A., Mariani, S. M., Krammer, P. H., Galle, P. R., & Stremmel, W. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2808 · Cited by 252
Self-citationTwo CD95 tumor classes with different sensitivities to antitumor drugs
Algeciras-Schimnich, A., Pietras, E. M., Barnhart, B. C., Legembre, P., Vijayan, S., Holbeck, S. L., & Peter, M. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2034995100 · Cited by 118
Metadata
- Authors
- Dhein, J., Daniel, P. T., Trauth, B. C., Oehm, A., Möller, P., & Krammer, P. H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1992-11
- Volume
- 149
- Issue
- 10
- Pages
- 3166-3173
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1558647085
- Cited by
- 278
- References
- 0
- FWCI
- 20.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.